HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Sagimet Biosciences (NASDAQ:SGMT) and maintained a price target of $32.
October 02, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Sagimet Biosciences, maintaining a price target of $32, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst suggests a positive outlook for Sagimet Biosciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100